WO2004002461A3 - Combination of pde5 inhibitors with angiotensin ii receptor antagonists - Google Patents

Combination of pde5 inhibitors with angiotensin ii receptor antagonists Download PDF

Info

Publication number
WO2004002461A3
WO2004002461A3 PCT/IB2003/002657 IB0302657W WO2004002461A3 WO 2004002461 A3 WO2004002461 A3 WO 2004002461A3 IB 0302657 W IB0302657 W IB 0302657W WO 2004002461 A3 WO2004002461 A3 WO 2004002461A3
Authority
WO
WIPO (PCT)
Prior art keywords
angiotensin
combination
receptor antagonists
pde5 inhibitors
pde5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2003/002657
Other languages
French (fr)
Other versions
WO2004002461A2 (en
Inventor
David Nathan Abraham Fox
Bernadette Hughes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Pfizer Inc
Original Assignee
Pfizer Ltd Great Britain
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2004517093A priority Critical patent/JP2005531627A/en
Priority to BR0312030-9A priority patent/BR0312030A/en
Priority to KR10-2004-7021041A priority patent/KR20050013156A/en
Priority to MXPA04012569A priority patent/MXPA04012569A/en
Priority to EP03761725A priority patent/EP1524996A2/en
Priority to CA002491002A priority patent/CA2491002A1/en
Application filed by Pfizer Ltd Great Britain, Pfizer Inc filed Critical Pfizer Ltd Great Britain
Priority to AU2003242895A priority patent/AU2003242895A1/en
Publication of WO2004002461A2 publication Critical patent/WO2004002461A2/en
Publication of WO2004002461A3 publication Critical patent/WO2004002461A3/en
Anticipated expiration legal-status Critical
Priority to NO20050400A priority patent/NO20050400L/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Combinations comprising a) an inhibitor of cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDES) and b) an angiotensin II receptor antagonist are useful for treating hypertension.
PCT/IB2003/002657 2002-06-26 2003-06-16 Combination of pde5 inhibitors with angiotensin ii receptor antagonists Ceased WO2004002461A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BR0312030-9A BR0312030A (en) 2002-06-26 2003-06-16 Combination of pde5 inhibitors with angiotensin ii receptor antagonists
KR10-2004-7021041A KR20050013156A (en) 2002-06-26 2003-06-16 Novel Combination
MXPA04012569A MXPA04012569A (en) 2002-06-26 2003-06-16 Combination of pde5 inhibitors with angiotensin ii receptor antagonists.
EP03761725A EP1524996A2 (en) 2002-06-26 2003-06-16 Combination of pde5 inhibitors with angiotensin ii receptor antagonists
CA002491002A CA2491002A1 (en) 2002-06-26 2003-06-16 Combination of pde5 inhibitors with angiotensin ii receptor antagonists
JP2004517093A JP2005531627A (en) 2002-06-26 2003-06-16 New mixed medicine
AU2003242895A AU2003242895A1 (en) 2002-06-26 2003-06-16 Combination of PDE5 inhibitors with angiotensin II receptor antagonists
NO20050400A NO20050400L (en) 2002-06-26 2005-01-25 New combination preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0214784.1 2002-06-26
GBGB0214784.1A GB0214784D0 (en) 2002-06-26 2002-06-26 Novel combination

Publications (2)

Publication Number Publication Date
WO2004002461A2 WO2004002461A2 (en) 2004-01-08
WO2004002461A3 true WO2004002461A3 (en) 2004-05-13

Family

ID=9939342

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/002657 Ceased WO2004002461A2 (en) 2002-06-26 2003-06-16 Combination of pde5 inhibitors with angiotensin ii receptor antagonists

Country Status (20)

Country Link
EP (1) EP1524996A2 (en)
JP (1) JP2005531627A (en)
KR (1) KR20050013156A (en)
CN (1) CN1662257A (en)
AR (1) AR040337A1 (en)
AU (1) AU2003242895A1 (en)
BR (1) BR0312030A (en)
CA (1) CA2491002A1 (en)
GB (1) GB0214784D0 (en)
GT (1) GT200300124A (en)
MX (1) MXPA04012569A (en)
NO (1) NO20050400L (en)
PA (1) PA8575501A1 (en)
PE (1) PE20040868A1 (en)
PL (1) PL375079A1 (en)
RU (1) RU2004136276A (en)
TW (1) TW200404546A (en)
UY (1) UY27863A1 (en)
WO (1) WO2004002461A2 (en)
ZA (1) ZA200409532B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
JPWO2004036162A1 (en) * 2002-07-26 2006-02-16 オリンパス株式会社 Image processing system
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
BRPI0502411A (en) * 2005-03-31 2006-11-28 Univ Minas Gerais process of developing substances as potent and selective inhibitors of phosphodiesterase isoforms of types 1 to 5 (pde1, pde2, pde3, pde4, pde5) based on diocleine, fluranol or analogs and their pharmaceutical compositions for the study and treatment of cardiovascular disease and associated products
ATE537832T1 (en) * 2005-06-10 2012-01-15 Dong A Pharm Co Ltd AGENT FOR PREVENTING AND TREATING LIVER DISEASE USING A PYRAZOLOPYRIMIDINE DERIVATIVE
WO2007010337A2 (en) * 2005-07-15 2007-01-25 Proxomed Medizintechnik Gmbh Use of phosphodiesterase type 5 inhibitors for the prevention and treatment of diseases or health disorders and dispensing system for said inhibitors
US7985756B2 (en) * 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007134136A2 (en) * 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
RU2345763C1 (en) * 2007-04-26 2009-02-10 ФГУ "Московский научно-исследовательский институт психиатрии Федерального агентства по здравоохранению и социальному развитию" Method for reduction and prevention of cardiovascular by-effects induced by application of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction in men

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463756A1 (en) * 1990-06-20 1992-01-02 Pfizer Limited Pyrazolopyrimidinone antianginal agents
WO1995019978A1 (en) * 1994-01-21 1995-07-27 Laboratoires Glaxo Wellcome S.A. Tetracyclic derivatives, process of preparation and use
WO1999024433A1 (en) * 1997-11-12 1999-05-20 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
WO2001027113A2 (en) * 1999-10-11 2001-04-19 Pfizer Limited PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES
WO2001027112A1 (en) * 1999-10-11 2001-04-19 Pfizer Limited 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
WO2002013798A2 (en) * 2000-08-11 2002-02-21 Pfizer Limited Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463756A1 (en) * 1990-06-20 1992-01-02 Pfizer Limited Pyrazolopyrimidinone antianginal agents
WO1995019978A1 (en) * 1994-01-21 1995-07-27 Laboratoires Glaxo Wellcome S.A. Tetracyclic derivatives, process of preparation and use
WO1999024433A1 (en) * 1997-11-12 1999-05-20 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
WO2001027113A2 (en) * 1999-10-11 2001-04-19 Pfizer Limited PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES
WO2001027112A1 (en) * 1999-10-11 2001-04-19 Pfizer Limited 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
WO2002013798A2 (en) * 2000-08-11 2002-02-21 Pfizer Limited Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BUDAVARI S ET AL: "The Merck Index", 2001, MERCK INDEX. ENCYCLOPEDIA OF CHEMICALS, DRUGS, AND BIOLOGICALS, RAHWAY, MERCK & CO, US, VOL. ED. 13, PAGE(S) 291, 645, 5099, 1000, 1223, 1224, 1502, 1628, 1629, 1767, XP002259715 *
FOGARI, ROBERTO (1) ET AL: "Different effect of valsartan and lisinopril on sildenafil use in hypertensive men with erectile dysfunction.", AMERICAN JOURNAL OF HYPERTENSION, (APRIL, 2002) VOL. 15, NO. 4 PART 2, PP 37A. HTTP://WWW.AJH-US.ORG. PRINT. MEETING INFO.: SEVENTEENTH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN SOCIETY OF HYPERTENSION NEW YORK, N.Y., USA MAY 14-18, 2002, XP001131927 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin

Also Published As

Publication number Publication date
BR0312030A (en) 2005-03-22
UY27863A1 (en) 2003-12-31
WO2004002461A2 (en) 2004-01-08
PE20040868A1 (en) 2004-11-25
AU2003242895A1 (en) 2004-01-19
TW200404546A (en) 2004-04-01
JP2005531627A (en) 2005-10-20
CA2491002A1 (en) 2004-01-08
CN1662257A (en) 2005-08-31
NO20050400L (en) 2005-03-29
ZA200409532B (en) 2006-06-28
GT200300124A (en) 2004-03-17
EP1524996A2 (en) 2005-04-27
PL375079A1 (en) 2005-11-14
RU2004136276A (en) 2005-09-10
MXPA04012569A (en) 2005-04-19
PA8575501A1 (en) 2003-12-30
KR20050013156A (en) 2005-02-02
GB0214784D0 (en) 2002-08-07
AR040337A1 (en) 2005-03-30

Similar Documents

Publication Publication Date Title
EP1085871A4 (en) QUINAZOLINONE INHIBITORS OF cGMP PHOSPHODIESTERASE
WO2001076574A3 (en) Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
EP1397142A4 (en) Pyrimidine inhibitors of phosphodiesterase (pde) 7
AU9102201A (en) Xanthine phosphodiesterase v inhibitors
WO2003017936A3 (en) Use of dppiv inhibitors as diuretic and anti-hypertensive agents
MY135909A (en) Treatment of pulmonary hypertension
AU2003238822A1 (en) Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
WO2002102314A3 (en) Purine inhibitors of phosphodiesterase (pde) 7
WO2006023944A3 (en) Pulmonary delivery of inhibitors of phosphodiesterase type 5
ATE362474T1 (en) PYRAZOLO(1,5-A)PYRIMIDINES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES
AU2001285163A1 (en) Quinoline inhibitors of cgmp phosphodiesterase
AU2003265349A1 (en) Pyrrolotriazine kinase inhibitors
AU2003254053A8 (en) Pyrazolopyrimidines as protein kinase inhibitors
AU2003276648A1 (en) Benzodiazepine inhibitors of mitochondial f¿1?f¿0? atp hydrolase and methods of inhibiting f¿1?f¿0? atp hydrolase
AU2003251559A1 (en) Heterocyclic inhibitors of kinases
NO20021781D0 (en) Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase
MXPA04000586A (en) Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor.
WO2003099194A3 (en) Pharmaceutical combination of pde5 inhibitors with ace inhibitors
IL163958A0 (en) Anxiolytic agents with reduced sedative and ataxideffects
BR0312030A (en) Combination of pde5 inhibitors with angiotensin ii receptor antagonists
AU2003249658A1 (en) Xanthine phosphodiesterase v inhibitor polymorphs
EP1496897A4 (en) INHIBITORS OF TYROSINE KINASES
EA200401137A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PDE4 INHIBITOR OR PDE3 / 4 AND ANTAGONIST OF HISTAMINE RECEPTOR
WO2005042022A3 (en) Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist
WO2005116195A3 (en) Method for identifying pde5-modulators

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004/09532

Country of ref document: ZA

Ref document number: 536827

Country of ref document: NZ

Ref document number: 200409532

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 3759/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003242895

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/012569

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1-2004-502072

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2003761725

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003814574X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2004517093

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2491002

Country of ref document: CA

Ref document number: 375079

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 1020047021041

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1200500093

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 1020047021041

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003761725

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003761725

Country of ref document: EP